Biomerica (NASDAQ:BMRA) and KORU Medical Systems (NASDAQ:KRMD) Head-To-Head Comparison

Biomerica (NASDAQ:BMRA) and KORU Medical Systems (NASDAQ:KRMD) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, risk, earnings, institutional ownership, analyst recommendations and valuation.

Profitability

This table compares Biomerica and KORU Medical Systems’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Biomerica	-115.50%	-142.81%	-77.83%
KORU Medical Systems	-4.03%	-10.63%	-6.51%

Risk & Volatility

Biomerica has a beta of 0.38, meaning that its share price is 62% less volatile than the S&P 500. Comparatively, KORU Medical Systems has a beta of 0.39, meaning that its share price is 61% less volatile than the S&P 500.

Institutional and Insider Ownership

22.3% of Biomerica shares are owned by institutional investors. Comparatively, 58.6% of KORU Medical Systems shares are owned by institutional investors. 12.3% of Biomerica shares are owned by company insiders. Comparatively, 18.5% of KORU Medical Systems shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Earnings & Valuation

This table compares Biomerica and KORU Medical Systems”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biomerica	$4.45 million	1.19	-$3.78 million	($1.64)	-1.05
KORU Medical Systems	$41.13 million	3.34	-$2.64 million	($0.04)	-74.75

KORU Medical Systems has higher revenue and earnings than Biomerica. KORU Medical Systems is trading at a lower price-to-earnings ratio than Biomerica, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current ratings and recommmendations for Biomerica and KORU Medical Systems, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biomerica	1	0	0	0	1.00
KORU Medical Systems	1	0	4	1	2.83

Biomerica presently has a consensus price target of $9.00, suggesting a potential upside of 423.26%. KORU Medical Systems has a consensus price target of $7.00, suggesting a potential upside of 134.11%. Given Biomerica’s higher possible upside, equities analysts plainly believe Biomerica is more favorable than KORU Medical Systems.

Summary

KORU Medical Systems beats Biomerica on 13 of the 15 factors compared between the two stocks.

About Biomerica

Biomerica, Inc., a biomedical technology company, develops, patents, manufactures, and markets diagnostic and therapeutic products for the detection and/or treatment of medical conditions and diseases worldwide. The company's diagnostic test kits are used to analyze blood, urine, nasal or fecal specimens from patients in the diagnosis of various diseases, food intolerances, and other medical complications; or to measure bacteria, hormones, antibodies, antigens, or other substances which may exist in the human body, stools, or blood in extremely small concentrations. It primarily sells its products for gastrointestinal diseases, food intolerances, and various esoteric tests at the physicians' offices and over-the-counter drugstores, and hospital/clinical laboratories. The company is also developing InFoods IBS, that uses a simple blood sample to identify patient-specific foods which may alleviate irritable bowel syndrome symptoms; and H. Pylori diagnostic test that indicates if a patient is infected with the H. Pylori bacteria. In addition, it develops products to indicate if a person has been infected by COVID-19. Biomerica, Inc. was incorporated in 1971 and is headquartered in Irvine, California.

About KORU Medical Systems

KORU Medical Systems, Inc. develops and manufactures medical devices and supplies in the United States and internationally. It offers the freedom infusion systems to deliver life-saving therapies to patients with chronic illnesses, such as primary immunodeficiency diseases, chronic inflammatory demyelinating polyneuropathy, and paroxysmal nocturnal hemoglobinuria. Its products include the FREEDOM60 syringe infusion system, the FreedomEdge syringe driver, HIgH-Flo subcutaneous safety needle sets, and precision flow rate tubing products. The company was incorporated in 1980 and is based in Mahwah, New Jersey.